The NHS should run a mile from the genome sequencing goldrush
By David King,
The Guardian
| 02. 07. 2019
Genomics England’s plans to move into paid-for genome sequencing of healthy people has done more than raise eyebrows in the scientific world. Last week a parade of the genomics great and good – who had clearly not been informed of the plans announced last week by Matt Hancock, the health secretary – wrote to the Times saying this would “create two-tier access to services, where people who can pay are able to access services that are denied to those who cannot”.
Others have pointed out that the plans will create extra pressure on GPs, who will have to deal with a flood of “worried well” patients coming to them with DNA test results.
The idea is that new “genomics volunteers” will pay for the sequencing and for its interpretation, while agreeing to donate the results in anonymous form to the Genomics England databank. The fact that the volunteers are being asked to pay for test results, delivered by a healthcare provider rather than a private genetic-testing company, must give them the impression that there are personal health benefits to...
Related Articles
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Staff, ScienceDaily | 01.05.2026
Scientists at UNSW Sydney have developed a new form of CRISPR technology that could make gene therapy safer while also resolving a decades-long debate about how genes are switched off. The research shows that small chemical markers attached to DNA
...
Following a long-standing CGS tradition, we present a selection of our favorite Biopolitical Times posts of the past year.
In 2025, we published up to four posts every month, written by 12 authors (staff, consultants and allies), some in collaboration and one simply credited to CGS.
These titles are presented in chronological order, except for three In Memoriam notices, which follow. Many more posts that are worth your time can be found in the archive. Scroll down and “VIEW...
By Jonathan Matthews, GMWatch | 12.11.2025
In our first article in this series, we investigated the dark PR tactics that have accompanied Colossal Bioscience’s de-extinction disinformation campaign, in which transgenic cloned grey wolves have been showcased to the world as resurrected dire wolves – a...